Raymond James & Associates’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-163,623
| Closed | -$671K | – | 4299 |
|
|
2022
Q1 | $671K | Sell |
163,623
-1,159
| -0.7% | -$4.21K | ﹤0.01% | 2879 |
|
|
2021
Q4 | $588K | Sell |
164,782
-4,219
| -2% | -$14.8K | ﹤0.01% | 2969 |
|
|
2021
Q3 | $615K | Sell |
169,001
-9,565
| -5% | -$38.7K | ﹤0.01% | 2912 |
|
|
2021
Q2 | $779K | Sell |
178,566
-20,847
| -10% | -$84.9K | ﹤0.01% | 2762 |
|
|
2021
Q1 | $820K | Buy |
199,413
+24,073
| +14% | +$104K | ﹤0.01% | 2640 |
|
|
2020
Q4 | $700K | Sell |
175,340
-1,254
| -0.7% | -$4.06K | ﹤0.01% | 2580 |
|
|
2020
Q3 | $477K | Sell |
176,594
-30,424
| -15% | -$84.2K | ﹤0.01% | 2660 |
|
|
2020
Q2 | $569K | Buy |
207,018
+28,248
| +16% | +$78.8K | ﹤0.01% | 2506 |
|
|
2020
Q1 | $422K | Buy |
178,770
+62,861
| +54% | +$214K | ﹤0.01% | 2535 |
|
|
2019
Q4 | $545K | Buy |
115,909
+74,204
| +178% | +$304K | ﹤0.01% | 2665 |
|
|
2019
Q3 | $140K | Buy |
41,705
+289
| +0.7% | +$952 | ﹤0.01% | 3351 |
|
|
2019
Q2 | $136K | Buy |
41,416
+2,623
| +7% | +$7.59K | ﹤0.01% | 3355 |
|
|
2019
Q1 | $118K | Buy |
38,793
+1,344
| +4% | +$4.36K | ﹤0.01% | 3365 |
|
|
2018
Q4 | $102K | Buy |
+37,449
| New | +$123K | ﹤0.01% | 3300 |
|
|
2018
Q1 | – | Sell |
-11,323
| Closed | -$23K | – | 3624 |
|
|
2017
Q4 | $23K | Hold |
11,323
| – | – | ﹤0.01% | 3334 |
|
|
2017
Q3 | $37K | Buy |
11,323
+1,231
| +12% | +$3.8K | ﹤0.01% | 3266 |
|
|
2017
Q2 | $32K | Buy |
+10,092
| New | +$28.6K | ﹤0.01% | 3215 |
|
Other funds holding ATRS
Raymond James & Associates's ATRS Position: Q2 2022 in Review
Raymond James & Associates sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 163,623 shares — an estimated $671K sold.
Raymond James & Associates first reported a position in ATRS in Q2 2017 and held it in 17 quarters. The position peaked at $820K in Q1 2021. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Raymond James & Associates reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Raymond James & Associates sold 163,623 Antares Pharma, Inc. shares in Q2 2022, an estimated $671K.
- Raymond James & Associates first reported a position in Antares Pharma, Inc. in Q2 2017 and held it in 17 quarters.
- Raymond James & Associates's Antares Pharma, Inc. position peaked at $820K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.